Increasing the upper age limit for recipients of hematopoietic stem cell transplantation (HCT)
naturally has also increased the age of the corresponding related donor population …

Abstract Development of de novo hematologic malignancies in donor cells after allogeneic
stem cell transplantation (allo-SCT) provides a useful in vivo model to study the process of …

Relapse of acute leukemia following hematopoietic stem cell transplantation (HSCT) usually
represents return of an original disease clone, having evaded eradication by pretransplant …

Organ and tissue transplant is now the treatment of choice for many end stage diseases. In
the recent years, there has been an increasing demand for organs but not a similar increase …

Leukemia in donor cells (donor cell leukemia; DCL) has been reported as a rare but severe
complication of allogeneic stem cell transplantation (SCT). However, the incidence, potential …

Transplant recipients have been reported to have an increased risk of solid cancers but most
studies are small and have limited ability to evaluate the interaction of host, disease, and …

ALTHOUGH MANY ASPECTS of the development of malignant tumors are still incompletely
understood, conditions have been identified under which malignancies develop at a higher …

Donor cell leukaemia (DCL) is a rare complication of allogeneic haematopoietic cell
transplantation (HCT). We have investigated the prevalence and outcome of donor cell …

Relapse of primary disease and occurrence of new cancers can cause significant morbidity
and mortality in recipients of autologous and allogeneic hematopoietic-cell transplantation …

In 1971, a case of donor cell-derived acute lymphoblastic leukemia was reported. 1 Since
then, donor cell-derived leukemia/lymphoma (DCL) cases, including those acquired from …